Advances in multi-omics are expanding how researchers study complex biological systems in biomedical research. By integrating genomics, epigenomics, transcriptomics, proteomics, and metabolomics, researchers can examine complex biological processes across multiple molecular layers. However, handling and interpreting vast, heterogeneous data present unique challenges, requiring advanced computational methods and data integration techniques. In clinical research, the value of multi-omics depends on how well these different data types are integrated, analysed, and interpreted alongside the biological or clinical question being studied.
Clinical multi-omics combines information across molecular layers to examine relationships that may not be apparent from a single omics dataset.
Multi-omics refers to the integrative analysis of various 'omics' layers, providing a broader understanding of biological systems and enhancing our insights into health and disease. Each 'omics' layer offers unique insights.
Genomics studies the complete set of DNA within an organism, providing insights into genetic variations that may contribute to disease susceptibility and treatment responses.
Epigenomics examines the chemical modifications on DNA and histone proteins that regulate gene expression without altering the DNA sequence, offering insights into how environmental factors affect gene activity.
Transcriptomics focuses on RNA transcripts produced by the genome, providing information on gene expression patterns in different conditions.
Proteomics analyses the entire set of proteins, their structures, and functions, which are the main executors of cellular functions.
Metabolomics studies the complete set of small-molecule chemicals within a biological sample, offering insights into metabolic changes associated with diseases and treatments.
Multi-omics brings information from these molecular layers together so relationships between them can be analysed in the context of health, disease, and treatment response. The datasets may be collected from the same samples or individuals, but they can also come from different samples or sources.
Multi-omics can be used in clinical research to investigate disease mechanisms, identify biomarkers, explore treatment response, and define biologically meaningful patient subgroups. The research question should also guide sample, assay, and omics modality selections so that the data generated are suitable for the intended analysis. The analytical approach should follow the research question, with the relevant molecular data linked where possible to phenotype, treatment history, clinical metadata, and study outcomes.
Personalised medicine tailors medical treatment to the individual characteristics of each patient. It involves the use of multi-omics data to understand the unique genetic, environmental, and lifestyle factors that contribute to an individual's health and disease state. By considering these specific factors, personalised medicine aims to optimise therapeutic outcomes and minimise side effects, providing a more targeted and effective approach to healthcare.
Utilising multi-omics data allows for precise disease classification by identifying unique molecular signatures. This can support more detailed disease classification and inform further biomarker evaluation. For instance, in oncology, analysing the genomic and proteomic profiles of tumours may help identify molecular characteristics associated with treatment selection or response.
Multi-omics helps identify specific molecular targets for therapeutic intervention, allowing for the development of drugs that specifically target these molecules. This approach is particularly relevant in cancer treatment, where therapies can be designed to attack specific mutations within cancer cells, although molecular findings still require appropriate biological and clinical validation.
The integration and analysis of multi-omics data requires sophisticated statistical methods. These methods are essential for handling the complexity and volume of data generated from various omics layers. The choice of integration method depends on the research objective, the modalities being combined, and how closely observations correspond across datasets.
Combining data from genomics, epigenomics, transcriptomics, proteomics, and metabolomics involves statistical, network-based, and machine learning approaches selected according to the study question and data structure. These methods help in synthesising data to reveal comprehensive biological insights.
An important distinction is whether the datasets are matched, partially matched, or unmatched. Measurements taken from the same individuals or samples provide a different integration problem from datasets generated across separate populations, experiments, or platforms, and the analysis method needs to reflect this structure. Matched datasets can support direct comparisons between modalities within the same observational units, whereas unmatched datasets require approaches that account for the absence of one-to-one correspondence between samples. Partially matched datasets may contain both paired and unpaired observations, which also affects method selection.
Once datasets have been prepared and an integration strategy defined, statistical, and computational methods can be selected according to the analytical objective rather than simply the availability of a particular technique.
Multi-omics data is high-dimensional, making it challenging to analyse. Techniques like Principal Component Analysis (PCA), Independent Component Analysis (ICA), and t-Distributed Stochastic Neighbour Embedding (t-SNE) are used to reduce dimensionality while preserving essential information. These approaches can help identify broad patterns, clusters, and sources of variation before more targeted modelling is undertaken.
Regression models, mixed-effects models, and generalised linear models (GLMs) are employed to understand relationships between different omics layers and their impact on health outcomes. These models can account for confounding factors and interactions between variables. The appropriate model depends on the outcome, study design, repeated measurements, and the relationships the analysis is intended to estimate.
Machine learning (ML) algorithms, including random forests, support vector machines (SVMs), and Neural networks, are used for predictive modelling and classification tasks. Artificial intelligence (AI) techniques, particularly deep learning, are increasingly applied to interpret complex omics data. The aim may be to classify samples, identify molecular signatures, or predict an outcome from multiple data types. Where models may contribute to clinical research decisions, performance estimates should account for the risk of overfitting.
Single-cell and spatial approaches add new detail to multi-omics analysis by preserving information about individual cells or tissue location. They also introduce different data structures that affect how modalities can be integrated and interpreted.
Single-cell multi-omics integrates multiple omic data types at the single-cell level to analyse molecular heterogeneity, identify rare cell subtypes, and understand cellular dynamics, which can make it useful for studying complex diseases, immunology, and neuroscience. For example, single-cell multi-omics can provide insights into tumour heterogeneity and reveal how different cell types within a tumour respond to therapy in cancer research.
Spatial multi-omics combines multiple omic data types (e.g. genomics, transcriptomics, proteomics) with spatial information about the tissue or cellular environment. By preserving the spatial context, spatial multi-omics allows researchers to map molecular features to specific locations within tissues or organs. This approach is particularly useful for understanding tissue architecture, identifying disease hotspots, and studying how molecular signals are spatially organized. It offers new insights into complex diseases, such as cancer, neurodegeneration, and developmental disorders.
Single-cell and spatial approaches can also create different integration structures across modalities. The way measurements correspond across cells, samples, or tissue locations affects the statistical methods that can be used.
Multi-omics analysis has to account for differences between data types as well as the scale and quality of the datasets themselves. These issues can affect both integration and the reliability of downstream findings.
One of the major hurdles in multi-omics is the complexity of integrating data from diverse omic layers, which are often generated using different technologies and have varying characteristics. Harmonising these datasets requires sophisticated computational models and careful attention to data quality, compatibility, and interpretation. Differences in measurement scale, missing data, technical noise, batch effects, and assay sensitivity can also create apparent patterns that need to be separated from genuine biological variation.
Multi-omics generates massive datasets, requiring substantial computational power and storage. The scalability of methods to process and analyse such large volumes of data remains a challenge, particularly in real-time clinical settings or large-scale population studies.
Generating a statistical signal is only part of the process. Multi-omics findings also need to be reproducible, appropriately validated and interpretable in the context of the original research question.
The lack of standardisation in multi-omics methodologies from sample collection to data analysis poses a significant challenge. Variations in experimental protocols, data processing, and platform choices can affect reproducibility, hindering the widespread adoption of multi-omics in both clinical and research settings. Consistent quality control, pre-processing, documentation, and validation are therefore important when findings need to be reproduced across datasets, laboratories, or studies. Analytical reproducibility concerns whether a result can be obtained consistently under comparable conditions. Additionally, biological or clinical validation addresses the question of whether the observed signal represents a meaningful biological relationship and, where relevant, is supported in the intended clinical context.
Multi-omics data can be highly complex and difficult to interpret. Extracting meaningful biological insights requires not only advanced computational tools but also a deep understanding of the underlying biology. Developing effective strategies for translating this data into actionable knowledge remains a work in progress. Increasing model complexity does not automatically make findings more useful. Where machine learning or AI methods are used, researchers also need to consider whether the resulting patterns can be explained, validated, and related back to the original research question.
Wider use of multi-omics depends on some practical constraints.
High-throughput multi-omics technologies can be costly, which limits access to these tools for some research groups or clinical settings. Cost remains one practical consideration, alongside access to the computational infrastructure and specialist expertise needed to manage and analyse multiple data types.
Translating multi-omics research into clinical practice requires appropriate validation and consideration of any regulatory requirements that apply to the intended use. Ensuring data privacy and ethical considerations is crucial. Clinical use also depends on multidisciplinary expertise across biology, bioinformatics, statistics, and clinical interpretation. Data interoperability and consistent standards are also important when molecular measurements need to be combined with clinical information held across different systems, platforms, formats, or organisations.
Multi-omics can provide information that would be difficult to obtain from a single molecular layer, but its value depends on more than generating additional data. The research question, structure of the available datasets, integration method, statistical analysis, and connection with relevant biological or clinical outcomes all affect how findings can be interpreted.
For clinical research, this means defining the intended use of multi-omics data early and selecting analytical methods that fit that purpose. Attention to data quality, reproducibility, validation, and interpretability can then help determine whether an observed multi-omics signal provides useful evidence or requires further investigation.
If you’re using multi-omics in clinical research, Quanticate’s statistical consultancy experts can support study design, data integration, and statistical analysis. Request a consultation below to discuss the requirements of your study.